In homogeneous catalysis, the catalyst is in the same phase as the reactant. The number of collisions between reactants and catalyst is at a maximum.In a patent, 72287-26-4, name is [1,1′-Bis(diphenylphosphino)ferrocene]dichloropalladium(II), introducing its new discovery. Safety of [1,1′-Bis(diphenylphosphino)ferrocene]dichloropalladium(II)
Discovery of GSK2656157: An optimized PERK inhibitor selected for preclinical development
We recently reported the discovery of GSK2606414 (1), a selective first in class inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK), which inhibited PERK activation in cells and demonstrated tumor growth inhibition in a human tumor xenograft in mice. In continuation of our drug discovery program, we applied a strategy to decrease inhibitor lipophilicity as a means to improve physical properties and pharmacokinetics. This report describes our medicinal chemistry optimization culminating in the discovery of the PERK inhibitor GSK2656157 (6), which was selected for advancement to preclinical development.
We¡¯ll also look at important developments in the pharmaceutical industry because understanding organic chemistry is important in understanding health, medicine, the role of 72287-26-4, and how the biochemistry of the body works.Safety of [1,1′-Bis(diphenylphosphino)ferrocene]dichloropalladium(II)
Reference£º
Chapter 1 An introduction to palladium catalysis,
Palladium/carbon catalyst regeneration and mechanical application method